The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE)

Behavioural Brain Research

Volumn 252, Issue , 2013, Pages 302-311

  Benson, Curtis A ^a,c   Wong, Grace ^c   Tenorio, Gustavo ^c   Baker, Glen B ^a,b   Kerr, Bradley J ^a,c  

^a Centre for Neuroscience   (Canada)

^b Neurochemical Research Unit   (Canada)

^c Department of Anesthesiology and Pain Medicine ^*  (Canada)

Author keywords

5 HT; EAE; GABA; MAO

Indexed keywords

4 AMINOBUTYRIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); BIOGENIC AMINE; DOPAMINE; NORADRENALIN; PHENELZINE; SEROTONIN;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN LEVEL; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DOPAMINE BRAIN LEVEL; DRUG EFFICACY; EXPLORATORY BEHAVIOR; FEMALE; FUNCTIONAL STATUS; GLIOSIS; IMMUNOCYTOCHEMISTRY; INNERVATION; LYMPHOCYTIC INFILTRATION; MOTONEURON; MOUSE; NONHUMAN; NOREPINEPHRINE BRAIN LEVEL; PRIORITY JOURNAL; SPINAL CORD; SPINAL CORD VENTRAL HORN; TREATMENT OUTCOME;

5-HT; EAE; GABA; MAO;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD4; CENTRAL NERVOUS SYSTEM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOPAMINE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EXPLORATORY BEHAVIOR; FEMALE; FREUND'S ADJUVANT; GAMMA-AMINOBUTYRIC ACID; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NOREPINEPHRINE; PEPTIDE FRAGMENTS; PHENELZINE; ROTAROD PERFORMANCE TEST; SEROTONIN; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880032819     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.06.019     Document Type: Article

References (48)

1. Compston A., Coles A. Multiple sclerosis. The Lancet 2008, 372(9648):1502-1517.
2. Barkhatova V.P., Zavalishin I.A., Askarova L., Shavratskii V., Demina E.G. Changes in neurotransmitters in multiple sclerosis. Neuroscience and Behavioral Physiology 1998, 28(4):341-344.
3. Stover J.F., Pleines U.E., Morganti-Kossmann M.C., Kossmann T., Lowitzsch K., Kempski O.S. Neurotransmitters in cerebrospinal fluid reflect pathological activity. European Journal of Clinical Investigation 1997, 27(12):1038-1043.
4. White S.R., Bhatnagar R.K., Bardo M.T. Norepinephrine depletion in the spinal cord gray matter of rats with experimental allergic encephalomyelitis. Journal of Neurochemistry 1983, 40(6):1771-1773.
5. Musgrave T., Tenorio G., Rauw G., Baker G.B., Kerr B.J. Tissue concentration changes of amino acids and biogenic amines in the central nervous system of mice with experimental autoimmune encephalomyelitis (EAE). Neurochemistry International 2011, 59(1):28-38.
6. Besser M.J., Ganor Y., Levite M. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both. Journal of Neuroimmunology 2005, 169(1-2):161-171.
7. Bhat R., Axtell R., Mitra A., Miranda M., Lock C., Tsien R.W., et al. Inhibitory role for GABA in autoimmune inflammation. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(6):2580-2585.
8. Sarchielli P., Di Filippo M., Candeliere A., Chiasserini D., Mattioni A., Tenaglia S., et al. Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. Journal of Neuroimmunology 2007, 188(1-2):146-158.
9. Yin J., Albert R.H., Tretiakova A.P., Jameson B.A. 5-HT(1B) receptors play a prominent role in the proliferation of T-lymphocytes. Journal of Neuroimmunology 2006, 181(1-2):68-81.
10. Levite M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Current Opinion in Pharmacology 2008, 8(4):460-471.
11. Hofstetter H.H., Mossner R., Lesch K.P., Linker R.A., Toyka K.V., Gold R. Absence of reuptake of serotonin influences susceptibility to clinical autoimmune disease and neuroantigen-specific interferon-gamma production in mouse EAE. Clinical and Experimental Immunology 2005, 142(1):39-44.
12. Simonini M.V., Polak P.E., Sharp A., McGuire S., Galea E., Feinstein D.L. Increasing CNS noradrenaline reduces EAE severity. Journal of Neuroimmune Pharmacology 2010, 5(2):252-259.
13. Olechowski C.J., Truong J.J., Kerr B.J. Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE). Pain 2009, 141(1-2):156-164.
14. Peruga I., Hartwig S., Thone J., Hovemann B., Gold R., Juckel G., et al. Inflammation modulates anxiety in an animal model of multiple sclerosis. Behavioural Brain Research 2011, 220(1):20-29.
15. Pollak Y., Orion E., Goshen I., Ovadia H., Yirmiya R. Experimental autoimmune encephalomyelitis-associated behavioral syndrome as a model of 'depression due to multiple sclerosis'. Brain, Behavior, and Immunity 2002, 16(5):533-543.
16. Polak P.E., Kalinin S., Feinstein D.L. Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 2011, 134(Pt. 3):665-677.
17. Samuels E.R., Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function. Part II. Physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans. Current Neuropharmacology 2008, 6(3):254-285.
18. Lydiard R.B. The role of GABA in anxiety disorders. Journal of Clinical Psychiatry 2003, 64(Suppl. 3):21-27.
19. Parent M.B., Habib M.K., Baker G.B. Time-dependent changes in brain monoamine oxidase activity and in brain levels of monoamines and amino acids following acute administration of the antidepressant/antipanic drug phenelzine. Biochemical Pharmacology 2000, 59(10):1253-1263.
20. Gitow A., Liebowitz M.R., Schneier F.R. MAOI Therapy of Social Phobia, in Progress in Psychiatry 1994, 225-254. American Psychiatric Press Inc.
21. Johnson M.R., Lydiard R.B., Ballenger J.C. MAOIs in Panic Disorder and Agoraphobia, in Progress in Psychiatry 1994, 205-224. American Psychiatric Press Inc.
22. Kennedy S.H., Holt A., Baker G.B. Monoamine oxidase inhibitors. Kaplan & Sadock's Comprehensive Textbook of Psychiatry 2009, 3154-3164. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia. 9th Edition. B.J. Sadock, V.A. Sadock, P. Ruiz (Eds.).
23. Wood P.L., Khan M.A., Moskal J.R., Todd K.G., Tanay V.A., Baker G.B. Aldehyde load in ischemia-reperfusion brain injury: neuroprotection by neutralization of reactive aldehydes with phenelzine. Brain Research 2006, 1122(1):184-190.
24. Clineschmidt B.V., Horita A. The monoamine oxidase catalyzed degradation of phenelzine-l-14C: an irreversible inhibitor of monoamine oxidase--II. Studies in vivo. Biochemical Pharmacology 1969, 18(5):1021-1028.
25. Clineschmidt B.V., Horita A. The monoamine oxidase catalyzed degradation of phenelzine-l-14C: an irreversible inhibitor of monoamine oxidase--I. Studies in vitro. Biochemical Pharmacology 1969, 18(5):1011-1020.
26. Popov N., Matthies H. Some effects of monoamine oxidase inhibitors on the metabolism of gamma-aminobutyric acid in rat brain. Journal of Neurochemistry 1969, 16(3):899-907.
27. MacKenzie E.M., Song M.S., Dursun S.M., Tomlinson S., Todd K.G., Baker G.B. Phenelzine: an old drug that may hold clues to the development of new neuroprotective agents. Bulletin of Clinical Psychopharmacology 2010, 20:179-186.
28. Baker G.B., Sowa B., Todd K.G. Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?. Journal of Psychiatry & Neuroscience 2007, 32(5):313-315.
29. Paslawski T., Knause E., Iqbal N., Coutts R.T., Baker G.B. Beta-Phenylethylidenehydrazine, a novel inhibitor of GABA transaminase. Drug Development Research 2001, 54:35-39.
30. Musgrave T., Benson C., Wong G., Browne I., Tenorio G., Rauw G., et al. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain, Behavior, and Immunity 2011.
31. Todd K.G., Baker G.B. GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. Journal of Affective Disorders 1995, 35(3):125-129.
32. Al-Nuaimi S.K., Mackenzie E.M., Baker G.B. Monoamine oxidase inhibitors and neuroprotection: a review. American Journal of Therapeutics 2012, 19(6):436-448.
33. McKenna K.F., Baker G.B., Coutts R.T. N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines. Naunyn-Schmiedeberg's Archives of Pharmacology 1991, 343(5):478-482.
34. Hayashi Y., Jacob-Vadakot S., Dugan E.A., McBride S., Olexa R., Simansky K., et al. 5-HT precursor loading: but not 5-HT receptor agonists, increases motor function after spinal cord contusion in adult rats. Experimental Neurology 2010, 221(1):68-78.
35. Zhou S.Y., Goshgarian H.G. 5-Hydroxytryptophan-induced respiratory recovery after cervical spinal cord hemisection in rats. Journal of Applied Physiology 2000, 89(4):1528-1536.
36. Markianos M., Koutsis G., Evangelopoulos M.E., Mandellos D., Karahalios G., Sfagos C. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis. Journal of Neurochemistry 2009, 108(1):158-164.
37. Zhong Z., Wheeler M.D., Li X., Froh M., Schemmer P., Yin M., et al. l-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent. Current Opinion in Clinical Nutrition and Metabolic Care 2003, 6(2):229-240.
38. Carmans S., Hendriks J.J., Thewissen K., Van den Eynden J., Stinissen P., Rigo J.M., et al. The inhibitory neurotransmitter glycine modulates macrophage activity by activation of neutral amino acid transporters. Journal of Neuroscience Research 2010, 88(11):2420-2430.
39. Sasabe J., Chiba T., Yamada M., Okamoto K., Nishimoto I., Matsuoka M., et al. D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. The EMBO Journal 2007, 26(18):4149-4159.
40. Stys P.K., Zamponi G.W., van Minnen J., Geurts J.J. Will the real multiple sclerosis please stand up? Nature reviews. Neuroscience 2012, 13(7):507-514.
41. Shi R., Rickett T., Sun W. Acrolein-mediated injury in nervous system trauma and diseases. Molecular Nutrition & Food Research 2011, 55(9):1320-1331.
42. Mendu S.K., Bhandage A., Jin Z., Birnir B. Different subtypes of GABA-A receptors are expressed in human, mouse and rat T lymphocytes. PLoS ONE 2012, 7(8):e42959.
43. Durk T., Panther E., Muller T., Sorichter S., Ferrari D., Pizzirani, et al. 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes. International Immunology 2005, 17(5):599-606.
44. McAlees J.W., Smith L.T., Erbe R.S., Jarjoura D., Ponzio N.M., Sanders V.M. Epigenetic regulation of beta2-adrenergic receptor expression in T(H)1 and T(H)2 cells. Brain, Behavior, and Immunity 2011, 25(3):408-415.
45. Sanders V.M. The beta2-adrenergic receptor on T and B lymphocytes: do we understand it yet?. Brain, Behavior, and Immunity 2012, 26(2):195-200.
46. McKenna F., McLaughlin P.J., Lewis B.J., Sibbring G.C., Cummerson J.A., Bowen-Jones D., et al. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. Journal of Neuroimmunology 2002, 132(1-2):34-40.
47. Chaitidis P., Billett E.E., O'Donnell V.B., Fajardo A.B., Fitzgerald J., Kuban R.J., et al. Th2 response of human peripheral monocytes involves isoform-specific induction of monoamine oxidase-A. Journal of Immunology 2004, 173(8):4821-4827.
48. Grant S.L., Shulman Y., Tibbo P., Hampson D.R., Baker G.B. Determination of d-serine and related neuroactive amino acids in human plasma by high-performance liquid chromatography with fluorimetric detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2006, 884(2.):278-282.